Melanoma — Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
Citation(s)
M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma